

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



Disclaimer: GSK has prepared this Q3 2026 pre-announcement aide memoire per our standard prior practice. It includes statements made in previous public communications by GSK as extracted from their original source and, therefore, by definition, they should only be taken as speaking as at the date they were initially made, and they do not reflect subsequent or recent events, circumstances, or developments. Any updates to these and other previously made statements would only be included in further communications by GSK to the market and the inclusion of the extracted statements herein should not be taken to indicate that they will not be updated in the future. Please read the Cautionary statement regarding forward-looking statement set out on page 328 of the Annual Report 2025 and "Guidance and Outlooks, assumptions and cautionary statements" on pages 52 and 53 of the Q2 2026 results release. Please read the definitions and reconciliations for non-IFRS measures on pages 14-19, 50 and 51 of the Q2 2026 results release and the annual report on Form 20-F for FY 2025.

Full-year 2026 guidance

Commentary from Q2 2026 stock-exchange announcement (page 2):

GSK reaffirms its full-year 2026 guidance at constant exchange rates (CER), with further specificity

- **Turnover:** Increase between 3% to 5%, at the upper half of the range.
- **Core operating profit:** Increase between 7% to 9%, at the upper half of the range.
- **Core earnings per share:** Increase between 7% to 9%, at the lower half of the range.

Core operating profit is expected to grow at the upper half of the range between 7% to 9% at CER. GSK continues to expect to deliver leverage at a gross margin level due to improved product mix from Specialty Medicines growth and continued operational efficiencies. In addition, GSK anticipates further leverage in Operating profit as we accelerate ongoing productivity initiatives and take a returns-based approach to SG&A investments, with SG&A now expected to be broadly stable. R&D is now expected to grow significantly ahead of sales as we accelerate investments in the pipeline as part of the Accelerate Growth programme while driving operational efficiencies. Royalty income is now expected to be at £850-900 million.

Core earnings per share is also expected to increase at the lower half of the range between 7% to 9% at CER, reflecting higher interest charges of around £800 million, including the impact of the Nuvalent acquisition, and the tax rate, which is expected to rise to around 17.5%, offset by the expected benefit from the share buyback programme. Expectations for non-controlling interests remain unchanged relative to 2025.

Acquisition of Nuvalent

GSK announced the completion of the acquisition of Nuvalent on 15 July 2026.

[GSK completes acquisition of Nuvalent, Inc. | GSK](#)

Key information for Q3 2026

Foreign exchange (FX)

We expect that the impact of FX on Q3 2026 sales will be around -1%. As a result of the mix of currency movements relative to the combination of costs, we expect that the negative impact of FX on Q3 2026 sterling Core operating profit will be more significant than the negative impact on sales.

Weighted average number of shares (WANS)

In June 2026 GSK completed the £2bn share buyback programme as announced at FY 2024.

Since 24 February 2025, the Company has purchased 123,939,156 Ordinary Shares, for an aggregate consideration of just under £2 billion, in line with the announced programme.

[Transaction in Own Shares - 15:00:00 29 Jun 2026 - GSK News article | London Stock Exchange](#)

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



The basic WANS in Q3 2026 was 4,009m, a reduction of 0.6% relative to 4,034m in Q3 2025.

The information below includes commentary from recent circulars, stock-exchange announcements, investor/analyst calls, and previously published outlook statements.

Commentary at previous results relating to quarterly phasing

Commentary on Q2 2026 results call:

We expect operating profit growth to be significantly Q4 weighted. And a number of factors lead to this, including productivity charges taken in Q4 last year, whilst Q3 is impacted by the consolidation and phasing of Nuvalent costs and the acquisition-related interest together with a tough tax comparator.

Growth CER	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Comments on Full year guidance and Q3
Specialty Medicines	+17%	+15%	+16%	+18%	+14%	+14%	FY: +LDD
Vaccines	-6%	+9%	+2%	+4%	+4%	+8%	FY: stable to +LSD
General Medicines	+0%	-6%	+4%	-1%	-6%	-9%	FY: -LSD to -MSD
Turnover	+4%	+6%	+8%	+8%	+5%	+5%	Expected to increase between 3% and 5% (upper half of range)
COGS	+1%	+7%	+7%	+4%	+0%	-6%	We expect gross margin to benefit from supply chain efficiencies and product mix. Note: Q4 2025 included supply chain charges of around £150m.
SG&A	+8%	-1%	+5%	+2%	-2%	+5%	We expect SG&A to be broadly stable. Note: Q4 2025 included charges of around £150m to fund further productivity initiatives. Q1 2026 growth +2% excluding benefit of IP settlements
R&D	+2%	+11%	+10%	+18%	+12%	+13%	Expected to grow significantly ahead of sales in the full year
Royalty income	+21%	+70%	+23%	+39%	+8%	-17%	FY guidance: £850 to £900m (2025 £879m) Q2 2025 benefited from an IP settlement relating to RSV.
Core operating profit	+5%	+12%	+11%	+18%	+10%	+7%	Expected to increase between 7% and 9% (upper half of range)
Core EPS	+5%	+15%	+14%	+14%	+9%	+9%	Expected to increase between 7% and 9% (lower half of the range)

Turnover

2026 full-year guidance: Expected to increase between 3% to 5% at CER, at the upper half of the range. (H1 +5%)

Specialty Medicines

2026 full-year outlook: Expected increase at a low double-digit percent at CER. (H1 +14%)

HIV

2026 full-year outlook: Expected increase of a high-single digit per cent at CER. (H1 +10%)

Commentary on Q4M long-acting portfolio on Q2 results call:

- Treatment: CUATRO, our three times a year phase III registrational study in suppressed-switch patients has begun, supporting potential approval in 2028. We remain confident that three times a year treatment will be transformational, not incremental, making long-acting treatment easier to choose, deliver and sustain, unlocking substantial switch opportunity from both oral therapy and existing Cabenuva, which will drive long-acting injectable market growth.
- PrEP: With registrational study data from EXTEND 4M anticipated in the second half of 2026 and approval in 2027, we remain confident it represents the optimal prevention option for both patients and providers..

Oncology

2026 US FDA approvals

Jideytro (zidesamtinib) was approved in the US for previously treated ROS1-positive non-small cell lung cancer on 22 July 2026.

The PDUFA date for the use of **neladalkib** in ALK-altered non-small cell lung cancer is 27 November 2026.

Commentary in Q2 Press release:

- **Jemperli** (Q2 +27%; YTD +33%) Continued strong growth in Q2 and YTD across all regions. US continued to grow double-digit, which reduced in Q2 as new patient starts moderated. Strong growth continued in Europe and International driven by launches and reimbursement expansion across markets.
- **Ojjaara** (Q2 +36%; YTD +35%) Higher patient uptake across the regions and from continued commercial launches across Europe and International markets. US volume growth in Q2 and YTD was partly offset by continuing pricing pressures.
- **Zejula** (Q2 -34%; YTD -23%). US continues to decline with volume impacted by the US FDA label update and new prior authorisation insurance requirements, with Q2 further impacted by unfavourable channel mix and returns adjustments. Europe declined due to increased competition.

Blenrep commentary on Q2 2026 results call: And finally, Blenrep, our community-ready antibody drug conjugate for multiple myeloma is building in line with our expectations.

- We now have approval in 49 countries and recently, we have gained reimbursement for Germany and Spain. In the UK, that's the country where Blenrep launched first, we are seeing a shift in second-line treatment, as shown, with Blenrep now leading in new patient starts.
- In the US, we are receiving positive feedback from physicians with strong intent to continue use. As we've said before, our approach is to go slow to ensure positive experience, helped by the J-code,

which is now in effect for Blenrep as well. As we enter the second half of the year, we will continue to focus on unlocking the community opportunity where the majority of the patients are.

Blenrep commentary on Q4 2025 results call: We continue to expect this to be a slow ramp up as we support prescribers and patients to ensure a positive first experience and robust adoption.

Respiratory, Immunology & Inflammation

Nucala commentary on Q2 2026 results call:

- We once again had strong global growth driven by the COPD launch and its halo effect on the other indications. In the US, new-to-brand prescriptions were up 69% with COPD driving more than 70% of the growth. Internationally, sales were up 18%, primarily driven by our success in China, where Nucala gained majority share of bio-naïve patients in COPD and already has NRDL listing in severe asthma and nasal polyps.

Exdensus commentary on Q2 2026 results call:

- We are continuing to build access and coverage with more than 50% of insured patients now being covered. The majority of new patients are coming from the bio-naïve population, which we expect will continue as around 70% of patients who could be on a biologic for severe asthma still are not.

2026 US FDA approval: Bepirovirsen has been accepted for priority review and granted Breakthrough Therapy Designation by the US FDA. The US FDA has assigned 26 October 2026 as the Prescription Drug User Fee Act (PDUFA) goal date.

[Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA | GSK.](#)

2025 US FDA approvals:

Nucala (mepolizumab) was approved by the US FDA on 22 May 2025 for use in adults with chronic obstructive pulmonary disease (COPD).

Exdensus (depemokimab) was approved by the US FDA on 16 December 2025 as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients aged 12 years and older.

Vaccines

2026 full-year outlook: Broadly stable to an increase at a low single-digit percentage. (H1 +6%)

Shingrix (Q2 +3%; H1 +12%)

Commentary in Q2 2026 press release: Q2 growth was driven by demand in Europe, partly offset by lower sales in International. US sales were broadly stable with lower demand and channel inventory utilisation offset by favourable pricing including prior period rebate adjustments which added 3ppts to Shingrix Q2 growth.

Commentary on Q1 2026 results call: Moving forward this year, we expect tougher comparators for Europe and Japan as most large immunisation programmes annualise.

Arexvy

Commentary in Q2 2026 press release: Strong growth in Q2 was the result of Australian tender deliveries and prior period rebate adjustments in the US.

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



Commentary from Q3 2025 press release: Q3 2025 growth was driven by Europe and International related to recommendation and reimbursement in Germany and tender deliveries in Canada and Spain.

RSV activity in the US is tracked by the CDC. [Interactive Dashboard | NREVSS | CDC](#)

Meningitis

Penmenvy US FDA approval: On 15 February 2025 GSK announced US FDA approval of *Penmenvy* (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years.

[Penmenvy, GSK's 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY | GSK](#)

Other Paediatric & Adult Vaccines: Q3 2025 benefited from higher demand for MMRV vaccines (*Priorix*), including a one-off sale of bulk antigen.

US paediatric vaccines

Commentary on Q4 2025 results call: We continue to monitor the evolving paediatric vaccine landscape in the US. At this time, insurance coverage remains as before and we expect the recent HHS changes to be manageable, given GSK's broad portfolio of vaccines.

General Medicines

Growth CER	Q1	Q2	Q3	Q4	FY
2024	+1%	+12%	+7%	+6%	+6%
2025	+0%	-6%	+4%	-1%	-1%
2026	-6%	-9%			LSD to MSD % decline

2026 full-year outlook: expected decline of mid-single digit to low single-digit percentage at CER. (H1 -7%).

Trelegy (Q2 -7%; H1 -3%)

Commentary in Q2 2026 press release: US declined in Q2 and YTD with volumes adversely impacted by Medicare benefit design changes and continued unfavourable pricing pressures as well as channel mix pricing adjustments impacting growth in Q2 by 5 ppts and YTD by 4 ppts. Strong volume growth in Europe and International was driven by patient demand, SITT class growth and increased market share.

Utebzi (tebipenem)

Utebzi was approved by the US FDA on 17 June 2026. [Utebzi \(tebipenem pivoxil\) approved in the US for adults with complicated urinary tract infections \(cUTIs\) | GSK](#)

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



Financials (Core)

Core operating profit

2026 full-year guidance: Core operating profit is expected to increase between 7% to 9% at CER, at the upper half of the range. (H1 +8%).

Cost of goods sold

2026 full-year outlook: GSK expects to deliver leverage at a gross margin level due to improved product mix from Specialty Medicines growth and continued operational efficiencies.

SG&A

2026 full-year outlook: GSK anticipates further leverage in Operating profit as we accelerate ongoing productivity initiatives and take a returns-based approach to SG&A investments, with SG&A now expected to be broadly stable.

R&D

2026 full-year outlook: R&D is now expected to grow significantly ahead of sales as we accelerate investments in the pipeline as part of the Accelerate Growth programme while driving operational efficiencies.

Royalty income

2026 full-year outlook: Royalty income is expected to be at £850-900 million.

Commentary from Q4 2025 stock-exchange announcement: The full year included historic royalties recognised in association with the settlement of an IP dispute.

In £ millions	Q1	Q2	Q3	Q4	Full year
2024	151	144	168	176	639
2025	180	246	208	245	879
2026	195	204			£850 to £900m

Associates

2026 full-year outlook: N/A

Net interest payable

In £ millions	Q1	Q2	Q3	Q4	Full year
2024	(132)	(148)	(114)	(138)	(532)
2025	(101)	(125)	(132)	(150)	(508)
2026	(143)	(121)			around £800m

2026 full-year outlook: we expect higher interest charges of around £800 million, including the impact of the Nuvalent acquisition (previous guidance £600m to £650m).

Tax

2026 full-year outlook: Core tax rate expected to be around 17.5%.

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



Core tax rate	Q1	Q2	Q3	Q4	Full year
2024	17.5%	17.9%	17.4%	13.5%	17.0%
2025	17.8%	17.5%	16.0%	17.3%	17.1%
2026	18.3%	17.1%			around 17.5%

Non-controlling interests

In £ millions	Q1 2025	Q2 2025	Q3 2025	Q4 2025	FY 2025	Q1 2026	Q2 2026
ViiV	154	172	171	194	691	168	186
Other	8	3	5	5	21	5	5
Total	162	175	176	199	712	173	191

Weighted average number of shares (WANS)

The basic WANS in Q3 2026 was 4,009m, a reduction of 0.6% relative to 4,034m in Q3 2025.

In millions*	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
WANS: Quarter	4,081	4,088	4,063	4,034	4,019	4,023	4,014	4,009
YoY change	+0.6%	+0.5%	-0.4%	-1.1%	-1.5%	-1.6%	-1.2%	-0.6%
WANS: Cumulative - Year to date	4,077	4,088	4,076	4,062	4,051	4,023	4,018	4,015
YoY change	+0.6%	+0.5%	+0.0%	-0.3%	-0.6%	-1.6%	-1.4%	-1.2%
Period end shares	4,081	4,085	4,047	4,026	4,013	4,020	4,007	4,009

*Excludes treasury shares and shares held by ESOP trusts

Core EPS

2026 full-year guidance: Core earnings per share is expected to increase between 7% to 9% at CER, at the lower half of the range. (H1 +9%).

Dividend

2026 full-year guidance: The expected dividend for 2026 is 70p per share.

Dividend per share (p)	Q1	Q2	Q3	Q4	Full year
2024 – paid	15.0	15.0	15.0	16.0	61.0
2025 – paid	16.0	16.0	16.0	18.0	66.0
2026 – expected	17.0	17.0			70.0 ¹

¹The actual full year dividend amount is determined by the Board of Directors with the FY 2026 results.

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



Q3 2026 Pre-Announcement Aide Memoire - Appendix

Historic London Stock Exchange (LSE) announcements and press releases

Since the beginning of Q3 2026, we have issued several LSE announcements and press releases, each of which can be accessed using the following links:

<https://www.gsk.com/en-gb/media/press-releases/>
<https://us.gsk.com/en-us/media/press-releases/>
<https://us.gsk.com/en-us/products/>
<https://www.gsk.com/en-gb/investors/stock-exchange-announcements/london-rns/>
<https://www.gsk.com/en-gb/investors/stock-exchange-announcements/new-york-sec/>

Recent updates

- 06 October 2026: [ViiV Healthcare's long-acting HIV treatment Cabenuva \(cabotegravir + rilpivirine\) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia | GSK](#)
- 14 September 2026: [GSK presents positive registrational data to potentially expand Jideytro \(zidesamtinib\) to first-line ROS1-positive non-small cell lung cancer | GSK](#)
- 13 September 2026: [Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China | GSK](#)
- 10 September 2026: [GSK's Shingrix \(Recombinant Zoster Vaccine\) prefilled syringe presentation approved in Japan | GSK](#)
- 01 September 2026: [GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data | GSK](#)
- 24 August 2026: [Jemperli \(dostarlimab\) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer | GSK](#)
- 24 August 2026: [Hibsago \(bepirovirsen\) approved in Japan as first and only functional cure for chronic hepatitis B | GSK](#)
- 29 July 2026: [Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 | GSK](#)
- 28 July 2026: [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK | GSK](#)
- 28 July 2026: [GSK's licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China | GSK](#)
- 27 July 2026: [ViiV Healthcare's 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV | GSK](#)

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



22 July 2026: [Jideytro \(zidesamtinib\) approved in the US for previously treated ROS1-positive non-small cell lung cancer | GSK](#)

21 July 2026: [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026 | GSK](#)

20 July 2026: [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds | GSK](#)

17 July 2026: [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough \(RCC\) | GSK](#)

13 July 2026: [Jemperli \(dostarlimab\) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer | GSK](#)

10 July 2026: [GSK's licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population | GSK](#)

09 July 2026: [Roy Jakobs to join GSK Board as Non-Executive Director | GSK](#)

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



Recent updates relating to business development

15 September 2026: [GSK to acquire potential best-in-class T cell-engager \(TCE\) for multiple myeloma from Chimagen Biosciences | GSK](#)

15 July 2026: [GSK completes acquisition of Nuvalent, Inc. | GSK](#)

24 June 2026: [GSK announces commencement of tender offer to acquire Nuvalent, Inc. | GSK](#)

09 June 2026: [GSK enters agreement to acquire Nuvalent, Inc. | GSK](#)

11 May 2026: [GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch | GSK](#)

15 April 2026: [GSK completes acquisition of 35Pharma Inc. | GSK](#)

01 April 2026: [ViiV completes changes to minority shareholding](#)

09 March 2026: [GSK and Alfasigma announce agreement on worldwide rights for linerixibat | GSK](#)

03 March 2026: [GSK completes acquisition of RAPT Therapeutics | GSK](#)

25 February 2026: [GSK enters agreement to acquire 35Pharma Inc.](#)

20 January 2026: [GSK enters agreement to acquire RAPT Therapeutics | GSK](#)

20 January 2026: [GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding | GSK](#)

For your reference, the following pages include tables with historical financial information.

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



Essential information for Q3 2026

Foreign exchange

Average rates Quarterly	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Key currencies							
US\$	1.26	1.34	1.33	1.33	1.35	1.34	1.34
€	1.20	1.18	1.16	1.14	1.15	1.15	1.17
Yen	193	194	198	206	211	213	213
Other currencies							
Australian dollar	2.03	2.09	2.05	2.02	1.95	1.90	1.90
Brazilian real	7.46	7.54	7.30	7.19	7.10	6.84	6.92
Canadian dollar	1.82	1.85	1.85	1.85	1.85	1.86	1.88
Chinese yuan	9.18	9.66	9.55	9.37	9.34	9.13	9.06
Indian rupee	108.9	114.3	117.4	118.1	123.8	126.6	128.1
<i>FX impact on turnover</i>	-2%	-5%	-1%	-2%	-3%	+0%	-1%
<i>FX impact on Core OP</i>	-1%	-7%	-3%	-4%	-5%	-1%	n/a
<i>FX impact on Core EPS</i>	-1%	-8%	-3%	-4%	-5%	+0%	n/a

Average rates Cumulative - YTD	3M 2025	6M 2025	9M 2025	12M 2025	3M 2026	6M 2026	9M 2026
Key currencies							
US\$	1.26	1.30	1.31	1.31	1.35	1.34	1.34
€	1.20	1.19	1.18	1.17	1.15	1.15	1.16
Yen	193	193	195	198	211	212	213
Other currencies							
Australian dollar	2.03	2.06	2.05	2.05	1.95	1.93	1.92
Brazilian real	7.46	7.50	7.43	7.37	7.10	6.97	6.95
Canadian dollar	1.82	1.84	1.84	1.84	1.85	1.85	1.86
Chinese yuan	9.18	9.42	9.46	9.44	9.34	9.24	9.18
Indian rupee	108.9	111.6	113.5	114.7	123.8	125.2	126.2
<i>FX impact on turnover</i>	-2%	-3%	-3%	-3%	-3%	-2%	-1%
<i>FX impact on Core OP</i>	-1%	-4%	-3%	-4%	-5%	-2%	n/a
<i>FX impact on Core EPS</i>	-1%	-4%	-4%	-4%	-5%	-3%	n/a

Period end rates	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Key currencies								
US\$	1.25	1.29	1.37	1.34	1.35	1.32	1.32	1.33
€	1.20	1.20	1.17	1.14	1.15	1.15	1.16	1.17
Yen	197	193	198	199	211	211	215	209

Q3 2026 Pre-Announcement Aide Memoire

Issued: Thursday 8th October 2026



Foreign exchange: Ready reckoner

Following the 2025 Full Year results, we provided the following ready reckoner to help estimate the expected impact of foreign exchange movements on core operating profit:

Currency	Impact on 2026 full year core operating profit
US dollar	10 cents movement in the average exchange rate for full year impacts Core operating profit by approximately +/- 8%
Euro	10 cents movement in the average exchange rate for full year impacts Core operating profit by approximately +/- 0.5%
Japanese yen	10 Yen movement in the average exchange rate for full year impacts Core operating profit by approximately +/- 1%
Canadian dollar	10 cents movement in the average exchange rate for full year impacts Core operating profit by approximately +/- 0.5%

Please note the ready reckoner does not include the impact of inter-company exchange gains or losses.

The slide also included 2025 currency sales exposure for GSK:

Currency	2025 currency sales exposure
US dollar	52%
Euro	19%
Japanese yen	4%
Other†	25%

†Other currencies that each represent more than 1% of GSK sales include Australian Dollar, Brazilian Real, Canadian Dollar, Chinese Yuan and Indian Rupee. In total, they accounted for 9% of GSK revenues in 2025

To illustrate underlying performance, it is the Group's practice to discuss its results in terms of CER growth. This represents growth calculated as if the exchange rates used to determine the results of overseas companies in Sterling had remained unchanged from those used in the comparative period. All commentaries are presented in terms of CER growth unless otherwise stated.

Investor Relations			
Constantin Fest	constantin.x.fest@gsk.com	+44 7831 826525	(London)
James Dodwell	james.x.dodwell@gsk.com	+44 7881 269 066	(London)
Mick Readey	mick.j.readey@gsk.com	+44 7990 339 653	(London)
Joanna Tuplin	joanna.e.tuplin@gsk.com	+44 7788 351 650	(London)
Sam Piper	samuel.x.piper@gsk.com	+44 7824 525 779	(London)
Dan Smith	daniel.6.smith@gsk.com	+44 7823 523885	(London)
Jeff McLaughlin	jeffrey.r.mclaughlin@gsk.com	+ 1 215 751 7002	(Philadelphia)
Frannie DeFranco	frances.p.defranco@gsk.com	+ 1 215 751 3126	(Philadelphia)